Memorial Sloan Kettering Cancer Center

Karyopharm to host investor event on Oct 31, 2024, featuring KOLs Dr. Raajit Rampal and Dr. John Mascarenhas, with a favorable study design update on the Phase 3 SENTRY study in JAKi naive myelofibrosis.

Genentech's Itovebi shows 57% reduction in disease progression or death risk, extending progression-free survival from 7.3 to 15.0 months in HR-positive, HER2-negative breast cancer, published in the New England Journal of Medicine. FDA approved Itovebi for PIK3CA-mutated cases.

Weill Cornell Medicine scientists received awards from the Starr Cancer Consortium to fund research on cancer mechanisms and treatments. Projects include AI-based detection of prostate cancer subtypes, targeting leukemia stem cells, and modulating inflammation to eradicate clonal stem cells.

Weill Cornell Medicine scientists received Starr Cancer Consortium grants for research on prostate cancer, leukemia stem cells, and clonal stem cells, aiming to develop novel treatment strategies.

The PYNNACLE trial's phase 2 portion is on track, evaluating rezatapopt monotherapy in advanced solid tumors with TP53 Y220C mutation and KRAS wild-type. The combination cohort with pembrolizumab is discontinued due to dose-limiting toxicities and lack of clinical benefit. A new phase 1b study with rezatapopt and azacitidine for AML/MDS with TP53 Y220C mutation is planned to begin in Q1 2025. Rezatapopt aims to restore wild-type p53 function and has shown a 38% ORR at the RP2D of 2000 mg.

The 19th Annual New York Lung Cancers Symposium will focus on early-stage lung cancer treatment strategies, including the role of immune checkpoint inhibitors in perioperative settings based on CheckMate 816, IMpower010, PEARLS, and ADAURA trials. The symposium will also discuss the benefits of osimertinib after definitive chemoradiotherapy in locally advanced NSCLC, particularly for EGFR-mutated tumors, as shown in the LAURA trial. The conference aims to provide an interactive and multidisciplinary approach to lung cancer treatment.

Ginger J. Gardner, MD, FACOG, discusses rising gynecological cancer diagnoses and initiatives to improve outcomes, including clinical trials for targeted therapies and efforts to understand tumor biology.

Neoadjuvant pembrolizumab plus chemotherapy showed greater pathologic regression (%RVT) vs placebo in early-stage NSCLC, with significant improvements in OS and EFS. Lower %RVT correlated with better EFS, and pembrolizumab outperformed placebo across all %RVT categories. The regimen led to higher pCR and mPR rates and was FDA-approved in 2023.

ImPact Biotech to present interim ENLIGHTED Phase 3 study results of Padeliporfin VTP for low-grade UTUC at EMUC 2024 in Lisbon.